There are currently 117 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are Florida, New York, California and Texas.
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NCT05964829
Recruiting
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/19/2025
Locations: Cleveland State University, Cleveland, Ohio
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Register for Updates
ECoG BMI for Motor and Speech Control
NCT03698149
Recruiting
Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/10/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: ALS, SCI - Spinal Cord Injury, Stroke, Multiple Sclerosis, Muscular Dystrophies
Register for Updates
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criter... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/09/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama +298 locations
Conditions: Multiple Sclerosis
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/09/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama +331 locations
Conditions: Multiple Sclerosis
Register for Updates
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248
Recruiting
Studies performed under 89-N-0045 are designed to examine the natural history of multiple sclerosis (MS) using MRI and immunological measures. In addition to studying the natural history of untreated patients, the natural history of patients receiving approved disease-modifying therapies of MS will be examined. In both cohorts of patients levels of disease activity on MRI will be compared with immunological characteristics in order to help identify disease mechanism. Patients with either definit... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
NCT03109288
Recruiting
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to. Objective: To see if signs of inflammation in CSF help predict a person s response to different drugs. Eligibility: People ages 18 and older who: * Are in protocol 09-I-003... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
NCT05051618
Recruiting
The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants. This is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching progr... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/06/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis, Major Depressive Disorder
Register for Updates
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06170970
Recruiting
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medicati... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/06/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue
Register for Updates
Dry Needling in Multiple Sclerosis
NCT06394310
Recruiting
The investigators are doing this study to see if a treatment called dry needling improves muscle spasticity (muscle tightness) in people who have Multiple Sclerosis. Dry needling involves using tiny needles, like those in acupuncture, to target some muscles, like calf muscles. It differs from traditional acupuncture as it focuses on treating or managing muscle spots, aiming to reduce muscle stiffness and pain. Dry needling may offer a minimally-invasive and medication-free approach to improve mu... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/05/2025
Locations: Mobility and Falls Lab, Kansas city, Kansas
Conditions: Multiple Sclerosis, Spasticity
Register for Updates
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
06/04/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Register for Updates
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
NCT05122559
Recruiting
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
06/03/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Register for Updates
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
NCT06668324
Recruiting
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/30/2025
Locations: Novartis Investigative site, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates